Glycomed Inc. (NASDAQ:GLYC) of Alameda, Calif., announcedWednesday the completion of a sale by the company of $50million in principal amount of 75 percent convertiblesubordinated debentures due 2003.

The debentures will be listed separately (NASDAQ:GLYCG). Theoffering was managed and underwritten by MontgomerySecurities and Hambrecht & Quist Inc. The underwriters havean option to sell an additional $7.5 million principal amount tocover over-allotments.

(c) 1997 American Health Consultants. All rights reserved.